Erratum: Regulation of the cell cycle and PI3K/Akt/mTOR signaling pathway by tanshinone I in human breast cancer cell lines (Mol Med Rep (2015) 11 ( 931‑939) DOI: 10.3892/mmr.2014.2819);Regulation of the cell cycle and PI3K/Akt/mTOR signaling pathway by tanshinone i in human breast cancer cell lines

Molecular Medicine Reports

Volumn 11, Issue 2, 2015, Pages 931-939

  Wang, Li ^a   Wu, Jianzhong ^b   Lu, Jianwei ^b   Ma, Rong ^b   Sun, Dawei ^a   Tang, Jinhai ^a,b  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Cell cycle; Pi3k Akt mTOR; Signaling pathway; Tanshinone I

Indexed keywords

2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; ABIETANE DERIVATIVE; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; CHROMONE DERIVATIVE; CYCLIN DEPENDENT KINASE; ENZYME INHIBITOR; MORPHOLINE DERIVATIVE; MTOR PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TANSHINONE; TARGET OF RAPAMYCIN KINASE;

APOPTOSIS; BREAST TUMOR; CELL CYCLE; CELL PROLIFERATION; DRUG EFFECTS; FEMALE; GENETICS; HUMAN; MCF 7 CELL LINE; METABOLISM; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMONES; CYCLIN-DEPENDENT KINASES; DITERPENES, ABIETANE; ENZYME INHIBITORS; FEMALE; HUMANS; MCF-7 CELLS; MORPHOLINES; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84916219290     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2021.12080     Document Type: Erratum

References (47)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
2. Lee WYW, Chiu LCM and Yeung JHK: Cytotoxicity of major tanshinones isolated from Danshen (Salvia miltiorrhiza) on HepG2 cells in relation to glutathione perturbation. Food Chem Toxicol 46: 328-338, 2008.
3. Liu JJ, Zhang Y, Lin DJ and Xiao RZ: Tanshinone IIA inhibits leukemia THP-1cell growth by induction of apoptosis. Oncol Rep 21: 1075-1081, 2009.
4. Su CC and Lin YH: Tanshinone IIA inhibits human breast cancer cells through increased Bax to Bcl-xL ratios. Int J Mol Med 22: 357-361, 2008.
5. Lee CY, Sher HF, Chen HW, et al: Anticancer effects of tanshinone I in human non-small cell lung cancer. Mol Cancer Ther 7: 3527-3538, 2008.
6. Nizamutdinova IT, Lee GW, Son KH, et al: Tanshinone I effectively induces apoptosis in estrogen receptor-positive (MCF-7) and estrogen receptor-negative (MDA-MB-231) breast cancer cells. Int J Oncol 33: 485-491, 2008.
7. Zhou LM, Zuo Z and Chow MSS: Danshen: An overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol 45: 1345-1359, 2005.
8. Li YL, Gong Y, Li LL, Abdolmaleky HM and Zhou JR: Bioactive tanshinone I inhibits the growth of lung cancer in part via downregulation of Aurora A function. Mol Carcinog 52: 535-543, 2012.
9. Paulovich AG and Hartwell LH: A checkpoint regulates the rate of progression through S phase in Saccharomyces cerevisiae in response to DNA damage. Cell 82: 841-847, 1995.
10. Walker JL and Assoian RK: Integrin-dependent signal transduction regulating cyclin D1 expression and G1 phase cell cycle progression. Cancer Metastasis Rev 24: 383-393, 2005.
11. Lew DJ and Kornbluth S: Regulatory roles of cyclin dependent kinase phosphorylation in cell cycle control. Curr Opin Cell Biol 8: 795-804, 1996.
12. Kawauchi K, Ogasawara T, Yasuyama M, Otsuka K and Yamada O: The PI3K/Akt pathway as a target in the treatment of hematologic malignancies. Anticancer Agents Med Chem 9: 550-559, 2009.
13. Downward J: Signal transduction-lipid-regulated kinases: Some common themes at last. Science 279: 673-674, 1998.
14. Foster KG and Fingar DC: Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony. J Biol Chem 285: 14071-14077, 2010.
15. Benjamin D, Colombi M, Moroni C and Hall MN: Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov 10: 868-880, 2011.
16. Justin C and Ben Ho P: Targeting the PI3K/Akt/mTOR pathway for breast cancer therapy. J Mammary Gland Biol Neoplasia 17: 205-216, 2012.
17. Zhang YJ, Dai Q, Sun DF, et al: mTOR signaling pathway is a target for the treatment of colorectal cancer. Ann Surg Oncol 6: 2617-2628, 2009.
18. Maira SM, Voliva C and Garcia-Echeverria C: Class IA phosphatidylinositol 3-kinase: from their biologic implication in human cancers to drug discovery. Expert Opin Ther Targets 12: 223-238, 2008.
19. Li XJ, Ji MH, Zhong SL, et al: MicroRNA-34a modulates chemosensitivity of breast cancer cells to adriamycin by targeting notch1. Arch Med Res 43: 514-521, 2012.
20. Strong AL, Strong TA, Rhodes LV, et al: Obesity associated alterations in the biology of adipose stem cells mediate enhanced tumorigenesis by estrogen dependent pathways. Breast Cancer Res 15:R102, 2013.
21. Mousavi M, Montazeri A, Mohagheghi MA,et al:Breast Cancer in Iran: An Epidemiological Review. Breast J 13:383-391, 2007.
22. Mosaddik MA: In vitro cytotoxicity of tanshinones isolated from Salvia miltiorrhiza Bunge against P388 lymphocytic leukemia cells. Phytomedicine 10: 682-685, 2003.
23. Nizamutdinova IT, Lee GW, Lee JS, et al: Tanshinone I suppresses growth and invasion of human breast cancer cells, MDA-MB-231, through regulation of adhesion molecules. Carcinogenesis 29 :1885-1892, 2008.
24. Trivedi PP, Roberts PC, Wolf NA and Swanborg RH: NK cells inhibit T cell proliferation via p21-mediated cell cycle arrest. J Immunol 174: 4590-4597, 2005.
25. Gong Y, Li Y, Abdolmaleky HM, Li L and Zhou JR: Tanshinones inhibit the growth of breast cancer cells through epigenetic modification of aurora A expression and function. PLoS One 7: e33656, 2012.
26. Gong Y, Li Y, Lu Y, et al: Bioactive tanshinones in Salvia miltiorrhiza inhibit the growth of prostate cancer cells in vitro and in mice. Int J Cancer 129: 1042-1052, 2011.
27. Hseu YC, Chen S C, Chen HC, Liao JW and Yang HL: Antrodia camphorata inhibits proliferation of human breast cancer cells in vitro and in vivo. Food Chem Toxicol 46: 2680-2688, 2008.
28. Denicourt C and Dowdy SF: Cip/Kip proteins: more than just CDKs inhibitors. Genes Dev 18: 851-855, 2004.
29. Gartel AL and Tyner AL: The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 1: 639-649, 2002.
30. Cheng YL, Lee SC, Lin SZ, et al: Anti-proliferative A549 human activity of Bupleurum scrozonerifolium in lung cancer cells in vitro and in vivo. Cancer Lett 222: 183-193, 2005.
31. Tokunaga E, Oki E, Egashira A, et al: Deregulation of the Akt pathway in human cancer. Curr Cancer Drug Targets 8: 27-36, 2008.
32. Manning BD and Cantley LC: AKT/PKB signaling: navigating downstream. Cell 129: 1261-1274, 2007.
33. Janku F, Mc Conkey DJ, Hong DS and Kurzrock R: Autophagy as a target for anticancer therapy. Nat Rev Clin Oncol 8: 528-539, 2011.
34. Deng R, Tang J, Ma JG, et al: PKB/Akt promotes DSB repair in cancer cells through upregulating Mre11 expression following ionizing radiation. Oncogene 30: 944-955, 2011.
35. Umemura S, Yoshida S, Ohta Y, Naito K, Osamura RY and Tokuda Y: Increased phosphorylation of Akt in triple-negative breast cancers. Cancer Sci 98: 1889-1892, 2007.
36. Vivanco I and Sawyers CL: The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501, 2002.
37. Krystal GW, Sulanke G and Litz J: Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy. Mol Cancer Ther 1: 913-922, 2002.
38. Liu JJ, Liu WD, Yang HZ, et al: Inactivation of PI3k/Akt signaling pathway and activation of caspase-3 are involved in tanshinone I-induced apoptosis in myeloid leukemia cells in vitro. Ann Hematol 89: 1089-1097, 2010.
39. Cai N, Dai SD, Liu NN, Liu LM, Zhao N and Chen L: PI3K/AKT/mTOR signaling pathway inhibitors in proliferation of retinal pigment epithelial cells. Int J Ophthalmol 5: 675-680, 2012.
40. Yang HL, Chen CS, Chang WH, et al: Growth inhibition and induction of apoptosis in MCF-7 breast cancer cells by antrodiacamphorata. Cancer Lett 231: 215-227, 2006.
41. Mandal D, Moitra PK, Saha S and Basu J: Caspase 3 regulates phosphatidylserine externalization and phagocytosis of oxidatively stressed erythrocytes. FEBS Lett 513: 184-188, 2002.
42. Jankiewicz M, Groner B and Desrivieres S: Mammalian target of rapamycin regulates the growth of mammary epithelial cells through the inhibitor of deoxyribonucleic acid binding Id1 and their functional differentiation through Id2. Mol Endocrinol 20: 2369-2381, 2006.
43. Carraway H and Hidalgo M: New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists. Breast Cancer Res 6: 219-224, 2004.
44. Vu C and Fruman DA: Target of rapamycin signaling in leukemia and lymphoma. Clin Cancer Res 16: 5374-5380, 2010.
45. Dazert E and Hall MN: mTOR signaling in disease. Curr Opin Cell Biol 23: 744-755, 2011.
46. Johnsen JI, Segerstrom L, Orrego A, et al: Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo. Oncogene 27: 2910-2922, 2008.
47. Chesler L, Schlieve C, Goldenberg DD, et al: Inhibition of phosphatidylinositol 3-kinase destabilizes MYCN protein and blocks malignant progression in neuroblastoma. Cancer Res 66: 8139-8146, 2006.